AiCuris Drug Letermovir (AIC246) Meets Primary Efficacy Endpoints in Phase 2 For Human ...
Trial shows a dose-dependent effect on the prevention of HCMV re-activation/re-infection and an excellent tolerability Wuppertal, Germany, February 14, 2012 / B3C newswire / - AiCuris GmbH &Co KG , a clinical stage biopharmaceutical company …